## **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

#### Name of entity

Melbourne IT Limited

#### ABN

21 073 716 793

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

<sup>†</sup>Class of \*securities issued or to be issued

Performance Rights (unlisted) (being a right to subscribe for a security within the meaning given to that expression by Section 92(1) of the Corporations Act)

Number of \*securities issued or to be issued (if known) or maximum number which may be issued

539,398 Performance Rights (unlisted)

Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)

#### Performance Rights

• 247,382 Performance Rights issued to the Managing Director and Chief Executive Officer under the Melbourne IT Long Term Incentive Plan FY2017 Grant approved by shareholders on 29 May 2017, vesting on or around March 2020, subject to the satisfaction of the performance hurdles measured and tested over the Performance Period from 1 January 2017 and ending on 31 December 2019; and

<sup>+</sup> See chapter 19 for defined terms.

- 292,016 Performance Rights issued to executive key management personnel (KMP) and other eligible senior executives under the Melbourne IT Long Term Incentive Plan FY2017 Grant, vesting on or around March 2020, subject to the satisfaction of the performance hurdles measured and tested over the Performance Period from 1 January 2017 and ending on 31 December 2019.
- Do the \*securities rank equally in all respects from the \*issue date with an existing \*class of quoted \*securities?

If the additional \*securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 5 Issue price or consideration

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) No, Performance Rights do not carry voting, dividend or any other rights of fully paid ordinary shares.

Upon vesting, any shares allocated in satisfaction of the Performance Rights will rank equally and in all respects with the existing class of fully paid ordinary shares.

Nil.

The Performance Rights are issued as part of the senior executive remuneration package. There is no amount payable for the issue of performance rights.

Performance Rights issued to the Managing Director and Chief Executive Officer and other executive key management personnel (KMP) pursuant to the Melbourne IT Long Term Incentive Plan.

For reference, a copy of the Melbourne IT Long Term Incentive Plan is available at the Corporate Governance page of the Company (<a href="http://melbourneit.info/investor-centre/corporate-governance">http://melbourneit.info/investor-centre/corporate-governance</a>)

<sup>+</sup> See chapter 19 for defined terms.

ба	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h <i>in</i>	Yes
	relation to the +securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	29 May 2017
6c	Number of *securities issued without security holder approval under rule 7.1	292,016 Performance Rights (Unlisted)
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A
6f	Number of *securities issued under an exception in rule 7.2	247,382 Performance Rights (Unlisted) (Exception 14)
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	17,236,919
7	<sup>+</sup> Issue dates	29 May 2017
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	
	Cross reference: item 33 of Appendix 3B.	

<sup>+</sup> See chapter 19 for defined terms.

		Number	+Class
8	Number and <sup>+</sup> class of all <sup>+</sup> securities quoted on ASX ( <i>including</i> the <sup>+</sup> securities in section 2 if applicable)	116,859,567	Ordinary shares
	,	Number	+Class
9	Number and *class of all *securities not quoted on ASX ( <i>including</i> the *securities in section 2 if applicable)	1,585,169	Performance Rights (unlisted)
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	No change to the dividend policy.	
Part	2 - Pro rata issue		
11	Is security holder approval required?	N/A	
12	Is the issue renounceable or non-renounceable?	N/A	
13	Ratio in which the *securities will be offered	N/A	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/A	
15	<sup>+</sup> Record date to determine entitlements	N/A	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A	
17	Policy for deciding entitlements in relation to fractions	N/A	
18	Names of countries in which the entity has security holders who will not be sent new offer documents	N/A	
	Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.		
	Cross reference, rule 7.7.	<u> </u>	
19	Closing date for receipt of acceptances or renunciations	N/A	

Number

+Class

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	<sup>+</sup> Issue date	N/A

<sup>+</sup> See chapter 19 for defined terms.

## Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34	Type (tick o	of <sup>+</sup> securities one)	
(a) (b)		*Securities described in Part 1  All other *securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully pa employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertil securities	
Entiti	es tha	t have ticked box 34(a)	
Addit	ional	securities forming a new class of securities	
Tick to docume		e you are providing the information or	
35		If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders	
36		If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over	
37		A copy of any trust deed for the additional *securities	
Entiti	es tha	t have ticked box 34(b)	
38		per of *securities for which ation is sought N/A	
39		s of *securities for which tion is sought N/A	

<sup>+</sup> See chapter 19 for defined terms.

40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A	
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment		
	• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now	N/A	
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	N/A	
Duota	ntion agreement		

#### $\mathbf{Q}_{1}$

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX 1 may quote the +securities on any conditions it decides.
- We warrant the following to ASX. 2
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted †quotation.

<sup>+</sup> See chapter 19 for defined terms.

• An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 1 June 2017

**Company Secretary** 

Print name: Edelvine Rigato

== == == ==

<sup>+</sup> See chapter 19 for defined terms.

## **Appendix 3B – Annexure 1**

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	100,726,097 Shares	
Add the following:		
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> </ul>	16,133,470 Shares	
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with shareholder approval</li> </ul>		
<ul> <li>Number of partly paid <sup>+</sup>ordinary securities that became fully paid in that 12 month period</li> </ul>		
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
<b>Subtract</b> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period		
"A"	116,859,567 Shares	

<sup>+</sup> See chapter 19 for defined terms.

0. 0.01.1.4.750.5.450			
Step 2: Calculate 15% of "A"			
"B"	0.15		
	[Note: this value cannot be changed]		
<b>Multiply</b> "A" by 0.15	17,528,935		
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used			
<b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <b>not counting</b> those issued:	292,016 Performance Rights		
Under an exception in rule 7.2			
Under rule 7.1A			
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>			
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>			
"C"	292,016 Performance Rights		
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1			
"A" x 0.15	17,528,935		
Note: number must be same as shown in Step 2			
Subtract "C"	292,016		
Note: number must be same as shown in Step 3			
<i>Total</i> ["A" x 0.15] – "C"	17,236,919		
	[Note: this is the remaining placement capacity under rule 7.1]		

<sup>+</sup> See chapter 19 for defined terms.

## Part 2

Rule 7.1A – Additional placement capacity for eligible entities			
Step 1: Calculate "A", the base figure from which the placement capacity is calculated			
N/A			
Step 2: Calculate 10% of "A"			
0.10			
Note: this value cannot be changed			
N/A			
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used			
N/A			
N/A			

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	N/A	
Note: number must be same as shown in Step 2		
Subtract "E"	N/A	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.10] – "E"	N/A	
	Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.